A recent study investigating the impact of TREM2-expressing TAMs in NSCLC underscored the critical role of TREM2+ TAMs in driving immunosuppression, highlighting TREM2+ TAMs as potential prognostic markers and predictors of response to immunotherapy [123]. This evidence concerns the gene TREM2 and non-small cell lung carcinoma.